Niramai Health Analytix
Category: AI in Healthcare
AI-powered, non-invasive, radiation-free breast cancer screening solution using thermal imaging and machine learning Niramai Health Analytix was founded in 2016. The company is led by Dr. Geetha Manjunath. Based in Bengaluru, India. Team size: 63. Total funding raised: $10M+ (Latest round July 2025). Latest round: Series A extension - $10M (July 2025). Key investors include Pi Ventures, Binny Bansal, Department for Promotion of Industry and Internal Trade, Dream Incubator, Ankur Capital.
- Founded
- 2016
- Headquarters
- Bengaluru, India
- Team size
- 63
- Total funding
- $10M+ (Latest round July 2025)
Value proposition
Provides accurate, affordable, portable, painless, and privacy-aware breast cancer screening suitable for women of all ages without radiation
Products and solutions
Thermalytix, SMILE-100 System, Mythri
Unique value
Only AI-based thermal imaging solution for breast cancer screening that is completely non-contact, radiation-free, and suitable for women of all ages including those under 45
Target customer
Hospitals, diagnostic centers, public health organizations, and individual women for home screening
Industries served
Healthcare, Medical Technology, Diagnostics, Artificial Intelligence
Technology advantage
Patented Thermalytix technology using AI/ML algorithms to analyze thermal images, automated cloud-hosted solution, operable by low-skilled workers, 39+ patents backing the technology
How they differentiate
Unique thermal imaging AI approach that is completely non-invasive, radiation-free, privacy-aware, and suitable for frequent screening across all age groups
Main competitors
Kheiron Medical Technologies, UE LifeSciences, Braster S.A., Docturnal
Key partnerships
Google Cloud, Action Pink (German NGO), Department of Health and Family Welfare Punjab, Molbio Diagnostics, Roche India
Notable customers
Apollo Clinics, HCG Cancer Hospitals, Rainbow Hospitals, Government of Punjab for large-scale screening programs
Major milestones
US FDA clearance for SMILE-100 System, European CE Mark approval, 39+ patents granted, 300,000+ women screened globally, Presence in 22+ countries, UN General Assembly address by CEO, Multiple international awards including World Bank Gender Award 2022
Growth metrics
300,000+ women screened, 200+ hospitals and screening centers, 22+ countries, ₹9.8 Cr+ revenue in FY24
Market positioning
Pioneer in affordable, accessible early-stage breast cancer screening with global presence in 22+ countries
Geographic focus
Primary focus on India with presence in 30+ cities, expanding globally with FDA clearance for US market
Patents and IP
39+ patents across US, India, and Singapore covering Thermalytix technology and AI/ML algorithms
About Dr. Geetha Manjunath
Over 25 years of research experience at Xerox Research Centre India as Lab Director and Hewlett-Packard Laboratories as Principal Research Scientist. Ph.D. in Computer Science from Indian Institute of Science, with expertise in AI, machine learning, and computer vision.
Official website: https://niramai.com/